The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
Open accessAbstract
BACKGROUND: Liquid biopsies have demonstrated that the constitutively active androgen receptor splice variant-7 (AR-V7) associates with reduced response and overall survival from endocrine therapies in castration-resistant prostate cancer (CRPC). However, these studies provide little information pertaining to AR-V7 expression in prostate cancer (PC) tissue. METHODS: Following generation and validation of a potentially novel AR-V7 antibody for IHC, AR-V7 protein expression was determined for 358 primary prostate samples and 293 metastatic biopsies. Associations with disease progression, full-length androgen receptor (AR-FL) expression, response to therapy, and gene expression were determined. RESULTS: We demonstrated that AR-V7 protein is rarely expressed (<1%) in primary PC but is frequently detected (75% of cases) following androgen deprivation therapy, with further significant (P = 0.020) increase in expression following abiraterone acetate or enzalutamide therapy. In CRPC, AR-V7 expression is predominantly (94% of cases) nuclear and correlates with AR-FL expression (P ≤ 0.001) and AR copy number (P = 0.026). However, dissociation of expression was observed, suggesting that mRNA splicing remains crucial for AR-V7 generation. AR-V7 expression was heterogeneous between different metastases from a patient, although AR-V7 expression was similar within a metastasis. Moreover, AR-V7 expression correlated with a unique 59-gene signature in CRPC, including HOXB13, a critical coregulator of AR-V7 function. Finally, AR-V7-negative disease associated with better prostate-specific antigen (PSA) responses (100% vs. 54%, P = 0.03) and overall survival (74.3 vs. 25.2 months, hazard ratio 0.23 [0.07-0.79], P = 0.02) from endocrine therapies (pre-chemotherapy). CONCLUSION: This study provides impetus to develop therapies that abrogate AR-V7 signaling to improve our understanding of AR-V7 biology and to confirm the clinical significance of AR-V7. FUNDING: Work at the University of Washington and in the Plymate and Nelson laboratories is supported by the Department of Defense Prostate Cancer Research Program (W81XWH-14-2-0183, W81XWH-12-PCRP-TIA, W81XWH-15-1-0430, and W81XWH-13-2-0070), the Pacific Northwest Prostate Cancer SPORE (P50CA97186), the Institute for Prostate Cancer Research, the Veterans Affairs Research Program, the NIH/National Cancer Institute (P01CA163227), and the Prostate Cancer Foundation. Work in the de Bono laboratory was supported by funding from the Movember Foundation/Prostate Cancer UK (CEO13-2-002), the US Department of Defense (W81XWH-13-2-0093), the Prostate Cancer Foundation (20131017 and 20131017-1), Stand Up To Cancer (SU2C-AACR-DT0712), Cancer Research UK (CRM108X-A25144), and the UK Department of Health through an Experimental Cancer Medicine Centre grant (ECMC-CRM064X).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Trapnell, C., Roberts, A., Goff, L., Pertea, G., Kim, D., Kelley, D. R., Pimentel, H., Salzberg, S. L., Rinn, J. L., & Pachter, L. (2012) · Nature Protocols · doi:10.1038/nprot.2012.016 · Cited by 12,116
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Molecular signatures database (MSigDB) 3.0
Liberzon, A., Subramanian, A., Pinchback, R., Thorvaldsdóttir, H., Tamayo, P., & Mesirov, J. P. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr260 · Cited by 7,111
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Self-citationAbiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Huggins, C., & Hodges, C. V. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64820-3 · Cited by 3,855
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
Self-citationThe Molecular Taxonomy of Primary Prostate Cancer
Abeshouse, A., Ahn, J., Akbani, R., Ally, A., Amin, S., Andry, C. D., Annala, M., Aprikian, A., Armenia, J., Arora, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.025 · Cited by 3,110
Self-citationEnzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
Self-citationAbiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Fizazi, K., Tran, N., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B. Y., Özgüroğlu, M., Ye, D., Feyerabend, S., Protheroe, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704174 · Cited by 2,308
Drug delivery with carbon nanotubes for in vivo cancer treatment
Liu, Z., Chen, K., Davis, C. R., Sherlock, S. P., Cao, Q., Chen, X. S., & Dai, H. (2008) · PubMed · doi:10.48550/arxiv.0808.2070 · Cited by 2,286
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Abiraterone for prostate cancer not previously treated with hormone therapy
James, N. D., de Bono, J. S., Spears, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Ritchie, A. W. S., Amos, C. L., Gilson, C., Jones, R. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702900 · Cited by 1,801
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484 · cited 1×
“EPR15656 primarily recognizes AR-V7 but may also bind other proteins demonstrating staining in PC3 cells, colorectal (liver) metastasis, normal lung epithelium, and cytoplasmic compartment (2, 28, 30).”
BackgroundMontgomery, R. B., Mostaghel, E. A., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., True, L. D., & Nelson, P. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0249 · Cited by 1,419
Self-citationRyan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F. A., Sternberg, C. N., Miller, K., Logothetis, C. J., Shore, N. D., Small, E. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71205-7 · Cited by 1,369
Hu, R., Dunn, T. A., Wei, S., Isharwal, S., Veltri, R. W., Humphreys, E., Han, M., Partin, A. W., Vessella, R. L., Isaacs, W. B., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2764 · Cited by 1,077
Self-citationGlucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
Arora, V. K., Schenkein, E., Murali, R., Subudhi, S. K., Wongvipat, J., Balbas, M. D., Shah, N., Cai, L., Efstathiou, E., Logothetis, C., et al. (2013) · Cell · doi:10.1016/j.cell.2013.11.012 · Cited by 986
Attard, G., Reid, A. H. M., Yap, T. A., Raynaud, F., Dowsett, M., Settatree, S., Barrett, M., Parker, C., Martins, V., Folkerd, E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9749 · Cited by 903
Self-citationDetre, S., Saclani Jotti, G., & Dowsett, M. (1995) · Journal of Clinical Pathology · doi:10.1136/jcp.48.9.876 · Cited by 880
Guo, Z., Yang, X., Sun, F., Jiang, R., Linn, D. E., Chen, H., Chen, H., Kong, X., Melamed, J., Tepper, C. G., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3795 · Cited by 880
Dehm, S. M., Schmidt, L. J., Heemers, H. V., Vessella, R. L., & Tindall, D. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0594 · Cited by 834
Cuzick, J., Swanson, G. P., Fisher, G., Brothman, A. R., Berney, D. M., Reid, J. E., Mesher, D., Speights, V., Stankiewicz, E., Foster, C. S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70295-3 · Cited by 792
Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer.
Linja, M. J., Savinainen, K., Saramäki, O. R., Tammela, T. L. J., Vessella, R. L., & Visakorpi, T. (2001) · PubMed · Cited by 774
Kumar, A., Coleman, I., Morrissey, C., Zhang, X., True, L. D., Gulati, R., Etzioni, R., Bolouri, H., Montgomery, B., White, T., et al. (2016) · Nature Medicine · doi:10.1038/nm.4053 · Cited by 738
Self-citationEGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition
中川, 学. (2014) · Institutional Repositories DataBase (IRDB) · Cited by 736
Li, Y., Chan, S. C., Brand, L. J., Hwang, T. H., Silverstein, K. A. T., & Dehm, S. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3630 · Cited by 680
Scher, H. I., Lu, D., Schreiber, N. A., Louw, J., Graf, R. P., Vargas, H. A., Johnson, A., Jendrisak, A., Bambury, R., Danila, D., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1828 · Cited by 641
Watson, P. A., Chen, Y. F., Balbas, M. D., Wongvipat, J., Socci, N. D., Viale, A., Kim, K., & Sawyers, C. L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012443107 · Cited by 639
Antonarakis, E. S., Lu, C., Luber, B., Wang, H., Chen, Y., Nakazawa, M., Nadal, R., Paller, C. J., Denmeade, S. R., Carducci, M. A., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1341 · Cited by 618
Self-citationHu, R., Lu, C., Mostaghel, E. A., Yegnasubramanian, S., Gurel, M., Tannahill, C., Edwards, J., Isaacs, W. B., Nelson, P. S., Bluemn, E., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3892 · Cited by 583
Self-citationIntegrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.06.053 · Cited by 571
Self-citationHörnberg, E., Ylitalo, E. B., Crnalic, S., Antti, H., Stattin, P., Widmark, A., Bergh, A., & Wikström, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019059 · Cited by 498
Antonarakis, E. S., Lu, C., Luber, B., Wang, H., Chen, Y., Zhu, Y., Silberstein, J. L., Taylor, M. N., Maughan, B. L., Denmeade, S. R., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.1961 · Cited by 466
Self-citationSingle-vector inducible lentiviral RNAi system for oncology target validation
Wiederschain, D., Susan, W., Chen, L., Loo, A., Yang, G., Huang, A., Chen, Y., Caponigro, G., Yao, Y.-M., Lengauer, C., et al. (2009) · Cell Cycle · doi:10.4161/cc.8.3.7701 · Cited by 441
Plasma AR and abiraterone-resistant prostate cancer
Romanel, A., Tandefelt, D. G., Conteduca, V., Jayaram, A., Casiraghi, N., Wetterskog, D., Salvi, S., Amadori, D., Zafeiriou, Z., Rescigno, P., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac9511 · Cited by 441
Self-citationRizzardi, A. E., Johnson, A. T., Vogel, R. I., Pambuccian, S. E., Henriksen, J., Skubitz, A. P., Metzger, G. J., & Schmechel, S. C. (2012) · Diagnostic Pathology · doi:10.1186/1746-1596-7-42 · Cited by 435
Viswanathan, S. R., Ha, G., Hoff, A. M., Wala, J. A., Carrot-Zhang, J., Whelan, C. W., Haradhvala, N. J., Freeman, S. S., Reed, S. C., Rhoades, J., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.036 · Cited by 365
Self-citationTakeda, D. Y., Spisák, S., Seo, J.-H., Bell, C., O’Connor, E., Korthauer, K., Ribli, D., Csabai, I., Solymosi, N., Szállási, Z., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.037 · Cited by 317
Mechanisms of the androgen receptor splicing in prostate cancer cells
Liu, L. L., Xie, N., Sun, S., Plymate, S., Mostaghel, E., & Dong, X. (2014) · Oncogene · doi:10.1038/onc.2013.284 · Cited by 315
Self-citationProduction and Titration of Lentiviral Vectors
Barde, I., Salmon, P., & Trono, D. (2010) · Current Protocols in Neuroscience · doi:10.1002/0471142301.ns0421s53 · Cited by 297
Del Re, M., Biasco, E., Crucitta, S., Derosa, L., Rofi, E., Orlandini, C., Miccoli, M., Galli, L., Falcone, A., Jenster, G. W., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.08.012 · Cited by 284
Conteduca, V., Wetterskog, D., Sharabiani, M. T. A., Grande, E., Fernandez-Perez, M. P., Jayaram, A., Salvi, S., Castellano, D., Romanel, A., Lolli, C., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx155 · Cited by 269
Efstathiou, E., Titus, M., Wen, S., Hoang, A., Karlou, M., Ashe, R., Tu, S. M., Aparicio, A., Troncoso, P., Mohler, J., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.05.005 · Cited by 248
Fizazi, K., Scher, H. I., Miller, K., Basch, E., Sternberg, C. N., Cella, D., Forer, D., Hirmand, M., & de Bono, J. S. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70303-1 · Cited by 208
Self-citationLi, Y., Hwang, T. H., Oseth, L. A., Hauge, A., Vessella, R. L., Schmechel, S. C., Hirsch, B., Beckman, K. B., Silverstein, K. A., & Dehm, S. M. (2012) · Oncogene · doi:10.1038/onc.2011.637 · Cited by 202
Li, Y., Alsagabi, M., Fan, D., Bova, G. S., Tewfik, A. H., & Dehm, S. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1998 · Cited by 199
Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer
Yu, Z., Chen, S., Sowalsky, A. G., Voznesensky, O. S., Mostaghel, E. A., Nelson, P. S., Cai, C., & Balk, S. P. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1863 · Cited by 196
Self-citationLoriot, Y., Miller, K., Sternberg, C. N., Fizazi, K., De Bono, J. S., Chowdhury, S., Higano, C. S., Noonberg, S., Holmstrom, S., Mansbach, H., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70113-0 · Cited by 191
Self-citationAndrogen Receptor Splice Variants Dimerize to Transactivate Target Genes
Xu, D., Zhan, Y., Qi, Y., Cao, B., Bai, S., Xu, W., Gambhir, S. S., Lee, P., Sartor, O., Flemington, E. K., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0381 · Cited by 189
Scher, H. I., Graf, R. P., Schreiber, N. A., McLaughlin, B., Lu, D., Louw, J., Danila, D. C., Dugan, L., Johnson, A., Heller, G., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.11.024 · Cited by 182
Serial blood-based analysis of AR-V7 in men with advanced prostate cancer
Nakazawa, M., Lu, C., Chen, Y., Paller, C. J., Carducci, M. A., Eisenberger, M. A., Luo, J., & Antonarakis, E. S. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv282 · Cited by 178
Self-citationHenzler, C., Li, Y., Yang, R., McBride, T., Ho, Y., Sprenger, C., Liu, G., Coleman, I., Lakely, B., Li, R., et al. (2016) · Nature Communications · doi:10.1038/ncomms13668 · Cited by 173
Self-citationEnzalutamide in Metastatic Prostate Cancer before Chemotherapy
(2014) · New England Journal of Medicine · doi:10.1056/nejmc1410239 · Cited by 172
Nyquist, M. D., Li, Y., Hwang, T. H., Manlove, L. S., Vessella, R. L., Silverstein, K. A. T., Voytas, D. F., & Dehm, S. M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1308587110 · Cited by 171
Qu, Y., Dai, B., Ye, D., Kong, Y., Chang, K., Jia, Z., Yang, X., Zhang, H., Zhu, Y., & Shi, G. (2015) · Scientific Reports · doi:10.1038/srep07654 · Cited by 161
Asangani, I. A., Wilder-Romans, K., Dommeti, V. L., Krishnamurthy, P. M., Apel, I. J., Escara-Wilke, J., Plymate, S. R., Navone, N. M., Wang, S., Feng, F. Y., et al. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0472 · Cited by 158
Self-citationDiverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13
Chen, Z., Wu, D., Thomas-Ahner, J. M., Lu, C., Zhao, P., Zhang, Q., Geraghty, C., Yan, P. S., Hankey, W., Sunkel, B., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718811115 · Cited by 158
Self-citationWelti, J. C., Sharp, A., Yuan, W., Dolling, D. I., Rodrigues, D. N., Figueiredo, I., Gil, V., Neeb, A., Clarke, M., Seed, G., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3571 · Cited by 156
Self-citationICGC Project on Early Onset Prostate Cancer, Gu, L., Frommel, S. C., Oakes, C. C., Simon, R., Grupp, K., Gerig, C. Y., Bär, D., Robinson, M. D., Baer, C. R., et al. (2014) · Nature Genetics · doi:10.1038/ng.3165 · Cited by 155
Laere, B. D., van Dam, P., Whitington, T., Mayrhofer, M., Diaz, E. H., den Eynden, G. V., Vandebroek, J., Del‐Favero, J., Laere, S. V., Dirix, L. Y., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.01.011 · Cited by 143
Miyamoto, D. T., Lee, R. J., Kalinich, M., LiCausi, J. A., Zheng, Y., Chen, T., Milner, J. D., Emmons, E., Ho, U. K., Broderick, K. T., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1406 · Cited by 135
Welti, J. C., Rodrigues, D. N., Sharp, A., Sun, S., Lorente, D., Riisnaes, R., Figueiredo, I., Zafeiriou, Z., Rescigno, P., Bono, J. S. D., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.03.049 · Cited by 123
Self-citationGlobal analysis of H3K27me3 as an epigenetic marker in prostate cancer progression
Ngollo, M., Lebert, A., Daures, M., Judes, G., Rifai, K. T., Dubois, L., Kémény, J., Penault-Llorca, F. M., Bignon, Y., Guy, L., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3256-y · Cited by 116
Todenhöfer, T., Azad, A., Stewart, C., Gao, J., Eigl, B. J., Gleave, M. E., Joshua, A. M., Black, P. C., & Chi, K. N. (2016) · The Journal of Urology · doi:10.1016/j.juro.2016.06.094 · Cited by 111
Qu, F., Xie, W., Nakabayashi, M., Zhang, H., Jeong, S. H., Wang, X., Komura, K., Sweeney, C. J., Sartor, O. A., Lee, G. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1070 · Cited by 108
Fan, L., Zhang, F., Xu, S., Cui, X., Hussain, A., Fazli, L., Gleave, M. E., Dong, X., & Qi, J. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802415115 · Cited by 107
Trock, B. J., Brotzman, M. J., Mangold, L. A., Bigley, J. W., Epstein, J. I., McLeod, D. G., Klein, E. A., Jones, J. S., Wang, S., McAskill, T., et al. (2011) · British Journal of Urology · doi:10.1111/j.1464-410x.2011.10718.x · Cited by 103
Ferraldeschi, R., Welti, J. C., Powers, M. V., Yuan, W., Smyth, T., Seed, G., Riisnaes, R., Hedayat, S., Wang, H., Crespo, M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2186 · Cited by 103
Self-citationGlycosylation is an Androgen-Regulated Process Essential for Prostate Cancer Cell Viability
Munkley, J., Vodák, D., Livermore, K., James, K., Wilson, B. T., Knight, B., McCullagh, P., Mcgrath, J., Crundwell, M., Harries, L., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.04.018 · Cited by 99
Seitz, A. K., Thoene, S., Bietenbeck, A., Nawroth, R., Tauber, R., Thalgott, M. K., Schmid, S. C., Secci, R., Retz, M. M., Gschwend, J. E., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.07.024 · Cited by 99
Sun, F., Chen, H.-G., Li, W., Yang, X., Wang, X., Jiang, R., Guo, Z., Chen, H., Huang, J., Borowsky, A. D., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.492140 · Cited by 96
Grzmil, M., Thelen, P., Hemmerlein, B., Schweyer, S., Voigt, S., Mury, D., & Burfeind, P. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63682-6 · Cited by 94
Krajewska, M., Smith, L. H., Rong, J., Huang, X., Hyer, M. L., Zeps, N., Iacopetta, B. J., Linke, S. P., Olson, A. H., Reed, J. C., et al. (2009) · Journal of Histochemistry & Cytochemistry · doi:10.1369/jhc.2009.952812 · Cited by 93
Tan, S., Petrovics, G., & Srivastava, S. K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041255 · Cited by 83
Ihlaseh, S. M., Drigo, S. A., de Jesus, C. M. N., Domingues, M. A. C., Filho, J. C. S. T., de Camargo, J. L. V., & Rogatto, S. R. (2013) · Histopathology · doi:10.1111/his.12226 · Cited by 66
Zhu, Y., Sharp, A., Anderson, C. M., Silberstein, J. L., Taylor, M. N., Lu, C., Zhao, P., Marzo, A. M. D., Antonarakis, E. S., Wang, M., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.08.009 · Cited by 65
Self-citationA role for STEAP2 in prostate cancer progression
Whiteland, H., Spencer-Harty, S., Morgan, C., Kynaston, H., Thomas, D. H., Bose, P., Fenn, N. J., Lewis, P., Jenkins, S. A., & Doak, S. H. (2014) · Clinical & Experimental Metastasis · doi:10.1007/s10585-014-9679-9 · Cited by 62
Morrissey, C. M., Roudier, M. P., Dowell, A., True, L. D., Ketchanji, M., Welty, C. J., Corey, E., Lange, P. H., Higano, C. S., & Vessella, R. L. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1749 · Cited by 61
Self-citationKim, S., Yang, X.-K., Li, Q., Wu, M., Costyn, L., Beharry, Z., Bartlett, M., & Cai, H.-J. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.798827 · Cited by 51
Russo, J. W., Gao, C., Bhasin, S. S., Voznesensky, O., Calagua, C., Arai, S., Nelson, P., Montgomery, B., Mostaghel, E., Corey, E., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0687 · Cited by 51
Self-citationLi, H., Wang, Z., Xiao, W., Yan, L., Guan, W., Hu, Z., Wu, L., Huang, Q., Wang, J., Xu, H., et al. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.74 · Cited by 47
Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer
Cato, L., Neeb, A., Sharp, A., Buzón, V., Ficarro, S. B., Yang, L., Muhle‐Goll, C., Kuznik, N. C., Riisnaes, R., Rodrigues, D. N., et al. (2017) · eLife · doi:10.7554/elife.27159 · Cited by 42
Self-citationChen, X., Bernemann, C., Tolkach, Y., Heller, M., Nientiedt, C., Falkenstein, M., Herpel, E., Jenzer, M., Grüllich, C., Jäger, D., et al. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.11.001 · Cited by 42
Guedes, L. B., Morais, C. L., Almutairi, F., Haffner, M. C., Zheng, Q., Isaacs, J. T., Antonarakis, E. S., Lu, C., Tsai, H. K., Luo, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0205 · Cited by 39
Self-citationKohli, M., Wang, L., Xie, F., Sicotte, H., Yin, P., Dehm, S. M., Hart, S. N., Vedell, P. T., Barman, P., Qin, R., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0145176 · Cited by 36
The androgen receptor malignancy shift in prostate cancer
Copeland, B. T., Pal, S. K., Bolton, E. C., & Jones, J. O. (2018) · The Prostate · doi:10.1002/pros.23497 · Cited by 36
KIBRA promotes prostate cancer cell proliferation and motility
Stauffer, S., Chen, X., Zhang, L., Chen, Y., & Dong, J. (2016) · FEBS Journal · doi:10.1111/febs.13718 · Cited by 33
Chen, H., Fan, P., Chang, S., Tsao, Y., Huang, H., & Chen, S. (2017) · Oncotarget · doi:10.18632/oncotarget.15308 · Cited by 33
Seed, G., Yuan, W., Mateo, J., Carreira, S., Bertan, C. M., Lambros, M. B. K., Boysen, G., Ferraldeschi, R., Miranda, S., Figueiredo, I., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0972 · Cited by 32
Self-citation
Cited by
Gillessen, S., Attard, G., Beer, T. M., Beltran, H., Bossi, A., Bristow, R., Carver, B., Castellano, D., Chung, B. H., Clarke, N., et al. (2018) · European Urology · doi:10.1016/j.eururo.2017.06.002 · Cited by 642
Self-citationHormonal Therapy for Prostate Cancer
Desai, K., McManus, J. M., & Sharifi, N. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab002 · Cited by 447
Gillessen, S., Attard, G., Beer, T. M., Beltran, H., Bjartell, A., Bossi, A., Briganti, A., Bristow, R. G., Chi, K. N., Clarke, N., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.01.012 · Cited by 389
Self-citationRice, M. A., Malhotra, S. V., & Stoyanova, T. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00801 · Cited by 309
Brady, L., Kriner, M., Coleman, I., Morrissey, C., Roudier, M., True, L. D., Gulati, R., Plymate, S. R., Zhou, Z., Birditt, B., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21615-4 · Cited by 297
Self-citation
Metadata
- Authors
- Sharp, A., Coleman, I., Yuan, W., Sprenger, C., Dolling, D., Rodrigues, D. N., Russo, J. W., Figueiredo, I., Bertan, C., Seed, G., Riisnaes, R., Uo, T., Neeb, A., Welti, J., Morrissey, C., Carreira, S., Luo, J., Nelson, P. S., Balk, S. P., True, L. D., de Bono, J. S., & Plymate, S. R.
- Venue
- Journal of Clinical Investigation
- Published
- 2018-11-26
- Volume
- 129
- Issue
- 1
- Pages
- 192-208
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2897146989
- Cited by
- 393
- References
- 94
- FWCI
- 26.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.